Belite Bio, Inc (NASDAQ: BLTE) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT BELITE BIO, INC

Belite Bio, Inc (NASDAQ: BLTE)
Listen to this Section


$139.56
-4.9000 ( -3.39% ) 105.2K

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Market Data


Open $139.56
Previous Close $144.46
Volume 105.2K
Market Cap $5.50B
Day Range $138.32 - $146.52
52 Week Range $56.10 - $200.00
Shares Outstanding 40.09M
Change % -3.39%
Net Change ▼ -4.9000
Insider Ownership N/A
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2022
CountryUnited States
UnderwriterThe Benchmark Company, more

Insider Ownership Transactions

Total Amount Purchased: 0.00

Date Type Amount Purchased Purchaser
No records found.

SEC Filings


Form Type Description Pages Date
6-k Form 6-K 3 Nov 10, 2025
6-k Form 6-K 6 Sep 08, 2025
6-k Form 6-K 3 Aug 11, 2025
6-k Form 6-K 5 Aug 07, 2025
6-k Form 6-K 4 Jul 02, 2025

Latest News


× Before browsing our site, please accept our cookies policy